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ABSTRACT
The JAK/STAT pathway is constitutively activated in myeloproliferative 
neoplasms and can be inhibited by ruxolitinib, a selective JAK1/2 inhibitor. The 
JAK2V617F mutation leads to constitutive STAT3 phosphorylation and potentially leads 
to inhibition of Stathmin 1 activity via STAT3. In support of this hypothesis, we found 
that, in HEL JAK2V617F cells, ruxolitinib treatment decreased STAT3 and Stathmin 1 
association, induced Stathmin 1 activation and microtubule instability. Silencing of 
Stathmin 1 significantly reduced cell proliferation and clonal growth, and increased 
apoptosis induced by ruxolitinib. Stathmin 1 silencing also prevented ruxolitinib-
induced microtubule instability. To phenocopy the effect of Stathmin 1 inhibition, cells 
were treated with paclitaxel, a microtubule-stabilizing drug, in association or not with 
ruxolitinib; combined treatment significantly increased apoptosis, when compared to 
monotherapy. Notably, Stathmin 1 mRNA levels were highly expressed in CD34+ cells 
from primary myelofibrosis patients. We then proposed that an undesired effect of 
ruxolitinib treatment may constitute Stathmin 1 activation and microtubule instability 
in JAK2V617F cells. Induction of microtubule stability, through Stathmin 1 silencing 
or paclitaxel treatment, combined with ruxolitinib could be an effective strategy for 
promoting apoptosis in JAK2V617F cells.
INTRODUCTION
Philadelphia chromosome-negative myeloproliferative 
neoplasms (MPNs), including essential thrombocythemia 
(ET), polycythemia vera (PV) and primary myelofibrosis 
(PMF), are characterized by increased myeloid proliferation, 
with predominant megakaryocytic, erythroid, and 
megakaryocytic/granulocytic expansion, respectively, and 
have a potential to leukemia transformation [1]. A gain of 
function mutation, V617F, in Janus kinase 2 (JAK2) gene 
has been reported in most PV cases and in more than half of 
ET and PMF cases [2]. However, the presence of multiple 
disease phenotypes and the absence of JAK2 mutation in 
some cases of MPN indicates that additional genetic lesions 
or/and aberrant signaling pathways may be involved in the 
pathogenesis and progression of the MPN [1, 2].
Stathmin 1, also named Oncoprotein 18 (OP18) or 
Leukemia-associated phosphoprotein p18 (LAP18), is a 
microtubule destabilizer that plays an important function 
in cell proliferation, clonogenicity, differentiation, motility 
and survival [3]. In normal hematopoiesis, high Stathmin 1 
expression correlates with the proliferative ability of early 
hematopoietic progenitors, and the downregulation of this 
protein is required for efficient cell differentiation [4, 5]. 
Stathmin 1 knockout mice presented two human-like 
phenotypes of hematopoietic disorders; megaloblastic 
Oncotarget29574www.impactjournals.com/oncotarget
anemia and thrombocytosis [6]. In malignant 
hematopoiesis, Stathmin 1 overexpression was reported 
in acute myeloid leukemia, acute lymphoid leukemia and 
myelodysplastic syndromes [7, 8, 9]. Notably, Stathmin 1 
silencing reduces cell proliferation and clonogenicity of 
leukemia cell lines [9, 10, 11].
Signaling pathways deregulated in MPN have the 
potential to regulate Stathmin 1 activity. For instance, 
PI3K, ERK1/2 and JNK1/2 regulate the activity of 
Stathmin 1 through its phosphorylation at serine 25 and/or 
38 [3, 12]. More importantly, activated STAT3 binds to 
and inhibits Stathmin 1, resulting in microtubule stability 
in non-Hodgkin lymphoma and gastric cancer human cell 
lines [13, 14], but Stathmin 1 has never been investigated 
in MPN. Thus, we aimed to investigate, in a JAK2V617F cell 
line, Stathmin 1 function and the effects of ruxolitinib on 
Stathmin 1 activation and cell phenotype. We also aimed 
to evaluate Stathmin 1 expression in CD34+ cells from 
BCR-ABL1 negative MPN patients.
RESULTS
Ruxolitinib treatment increases microtubule 
instability
Given that STAT3 binds to and inhibits Stathmin 1 
in non-Hodgkin lymphoma and gastric cancer human cell 
lines [13, 14], we first confirmed the association of STAT3 
and Stathmin 1 in HEL cells, which was abrogated by 
ruxolitinib treatment (Figure 1A), possibly due to STAT3 
phosphorylation inhibition induced by ruxolitinib [15]. 
Next, we evaluated the effects of ruxolitinib treatment 
on Stathmin 1 activity and microtubule stability by 
assessment of Stathmin 1 serine 16 phosphorylation 
(an inhibitory site), alpha-tubulin acetylation (a marker 
of microtubule stability) and confocal analysis of 
microtubule networks in the JAK2V617F cell model. In 
HEL cells, ruxolitinib treatment induced a slight decrease 
in Stathmin 1 phosphorylation and a marked reduction 
of alpha-tubulin acetylation, indicating increased 
microtubule instability (Figure 1B). Confocal analysis 
corroborated our results obtained with the microtubule 
stability markers, evidencing that ruxolitinib-treated 
HEL cells present a more diffuse microtubule network 
(Figure 1C).
Stathmin 1 silencing reduces cell proliferation 
and clonogenicity, and increases the pro-
apoptotic effects of ruxolitinib
In order to investigate the function of Stathmin 1 in 
a JAK2V617F cell line, HEL cells were stably transduced 
with lentiviral constructs encoding shRNA targeting 
Stathmin 1 (shSTMN1) or a shRNA targeting a control 
sequence (shControl). After polyclonal cell selection 
with puromycin, the efficient Stathmin 1 silencing was 
verified by qPCR and Western blotting (Figure 2A). 
We next evaluated the effect of Stathmin 1 silencing on 
cell viability and proliferation, in the presence or not of 
the selective JAK1/2 inhibitor ruxolitinib. Stathmin 1 
silencing significantly reduced cell viabilty compared to 
control cells, and had an additive effect with ruxolitinib 
treatment (p < 0.05, Figure 2B). Ki-67 analysis revealed 
that Stathmin 1 silencing significantly reduced cell 
proliferation, but did not have additive effects with 
ruxolitinib treatment on cell proliferation (Figure 2C). 
Regarding long-term proliferative potential, Stathmin 1 
silencing significantly reduced the number of colonies 
(p < 0.05, Figure 2D). Since ruxolitinib treatment (100 nM 
and 300 nM) strongly decreased colony formation, no 
further effect of Stathmin 1 inhibition on colony numbers 
was observed (Figure 2D), except in very low dose of 
ruxolitinib (10 nM; Supplementary Figure 1).
We then investigated whether the Stathmin 
1-silencing-induced decreased cell number was also due 
to increased apoptosis. Flow cytometry analysis revealed 
that Stathmin 1 silencing did not alter apoptosis in 
DMSO-treated HEL cells. However, Stathmin 1 silencing 
significantly increased apoptosis induced by ruxolitinib 
treatment at 300 nM (p < 0.01, Figure 3). Taken together, 
these results indicate that Stathmin 1 silencing alone 
decreases the proliferation and colony formation of 
HEL cells. When combined with ruxolitinib, Stathmin 1 
silencing amplifies ruxolitinib-induced apoptosis in 
JAK2V617F cells.
Inhibition of JAK2/STAT3 signaling increases 
Stathmin 1 activity and microtubule instability 
in HEL cells
The effects of Stathmin 1 silencing, in combination or 
not with ruxolitinib treatment, on microtubule dynamics and 
apoptosis were assessed by the evaluation of alpha-tubulin 
acetylation and caspase 3/PARP1 cleavage, respectively. 
Immunoblotting analysis of shControl cells treated with 
ruxolitinib revealed decreased alpha-tubulin acetylation 
levels, indicating increased microtubule instability. In 
contrast, Stathmin 1 silencing increased acetyl-alpha-
tubulin levels and prevented the loss of microtubule stability 
induced by ruxolitinib. As expected, ruxolitinib treatment 
reduced JAK2 and STAT3 phosphorylation levels in both 
shSTMN1 and shControl cells (Figure 4). In agreement 
with Annexin V staining results, the levels of cleaved 
caspase 3 and cleaved PARP1 increased upon ruxolitinib 
treatment, and higher levels of caspase 3/PARP1 cleavage 
were observed in shSTMN1 compared with shControl cells 
treated with 300 nM ruxolitinib (Figure 4). These results 
indicate that Stathmin 1 is involved in the microtubule 
instability during ruxolitinib treatment, possibly due to the 
downregulation of STAT3 activity.
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Paclitaxel-induced microtubule stability 
improves ruxolitinib response
We next sought to evaluate whether 
pharmacological induction of microtubule stability 
by paclitaxel improved the response to ruxolitinib 
treatment, in a manner similar to the of Stathmin 1 
silencing. Notably, paclitaxel combined with ruxolitinib 
treatment resulted in a greater reduction in cell viability 
and higher levels of apoptosis, compared with each 
treatment alone (Figure 5; p < 0.05). Western blot 
analysis indicated that paclitaxel was able to induce 
Stathmin 1 phosphorylation at serine 16 (an inhibitory 
site), overlapping the ruxolitinib effect and maintaining 
high levels of microtubule stability (Figure 6). 
Accordingly, paclitaxel plus ruxolitinib treatment 
resulted in increased levels of cleaved caspase 3 and 
cleaved PARP1 compared with paclitaxel or ruxolitinib 
alone (Figure 6).
Stathmin 1 is highly expressed in primary 
myelofibrosis patients
Aberrant Stathmin 1 expression has been 
described in several hematological malignancies, 
including lymphomas [8, 16], acute leukemias [7, 9, 17] 
and myelodysplastic syndromes [9, 18]. In addition, 
leukemia-related oncogenes, including BCR-ABL1 [19] 
and PML-RARα [20], have been associated with 
Stathmin 1 upregulation. Thus, we investigated Stathmin 
Figure 1: Ruxolitinib treatment induces microtubule instability. A. Immunoprecipitation (IP) with anti-STAT3 and 
immunobloting (IB) with anti-Stathmin 1 in total extracts from HEL cells, treated or not with ruxolitinib (300 nM). Isotype IgG antibody 
was used as a negative control of the immunoprecipitation; total cell extracts were used as positive controls for immunoblotting. B. Western 
blot analysis for Stathmin 1 serine 16 phosphorylation (an inhibitory site) (p-Stathmin 1S16) and alpha-tubulin acetylation (a marker of 
microtubule stability) (Ac-α-TubulinL40) levels in total cell extracts from HEL cells treated or not with different concentration of ruxolitinib 
(100 and 300 nM). The antibodies used for immunoblotting (IB) are indicated. The decreased p-Stathmin 1 and Ac-α-Tubulin levels 
indicate Stathmin 1 activation and microtubule instability upon ruxolitinib treatment. Immunoblotting for phospho STAT3 and total 
STAT3 confirmed the inhibitory effect of ruxolitinib on STAT3 activation; actin was used as a loading control. C. Confocal analysis of 
HEL cells, treated or not with different concentration of ruxolitinib (100 and 300 nM), displaying α-Tubulin (green) and DAPI (blue) 
staining;  MERGE shows the overlapped images. Scale bars are shown in the figure (10 μm). Note more diffuse microtubule networks in 
ruxolutinib-treated cells.
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Figure 2: Stathmin 1 silencing reduces cell proliferation and clonogenicity. A. Stathmin 1 mRNA and protein expression in HEL 
cells transduced with lentivirus-mediated shRNA control (shControl) or Stathmin 1 (shSTMN1). The antibodies used for immunoblotting 
(IB) are indicated. B. Cell viability was determined by MTT assay after 48 hours of incubation of shSTMN1 and normalized by the 
corresponding shControl cells. Results are shown as mean ± SD of six independent experiments; *p < 0.05, **p < 0.01; Mann–Whitney 
test. C. Ki-67 mean of fluorescence intensity (M.F.I.) was determinated by flow cytrometry after incubation of shSTMN1 for 48 h and 
normalized by the correponding shControl cells. Results are shown as mean ± SD of four independent experiments; *p < 0.05, Student 
t test. D. Colonies containing viable cells were detected by MTT after 10 days of culture of shSTMN1 and normalized by the corresponding 
shControl cells. Colony images are representative of one experiment and the bar graphs show the mean ± SD of at least six independent 
experiments; ***p < 0.0001; Student t test. The assays were performed in the presence or not of ruxolitinib (100 and 300 nM) as indicated.
Figure 3: Stathmin 1 inhibition increases the pro-apoptotic effects of ruxolitinib treatment. A. Apoptosis was detected by 
flow cytometry in HEL cells transduced with shControl and shSTMN1 using Annexin-V/PI staining method and a representative dot plot 
is illustrated. B. Bar graphs show the mean ± SD of six independent experiments; **p < 0.01; Student t test. The assays were performed in 
the presence or not of ruxolitinib (100 and 300 nM) as indicated.
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1 expression in PB CD34+ cells from healthy donors and 
patients with PV, ET and PMF and we also stratified 
the MPN patients according to the presence, or not, of 
JAK2V617F and CALR mutations. Stathmin 1 transcripts 
were significantly increased in PB CD34+ cells from 
PMF patients, compared with healthy donors (median 
2.73 [range 0.49–8.32] vs. 1.08 [0.08–7.17], respectively, 
p = 0.005); however no significant difference in Stathmin 
1 expression was observed in PB CD34+ cells from ET 
(1.10 [range 0.07–6.98]) and PV (0.98 [0.18–6.02]) 
patients, compared with healthy donors (Figure 7A). 
Stathmin 1 expression did not differ in MPN patients 
when stratified according to JAK2 mutation status 
(JAK2WT = 1.08 [range 0.07–6.99] vs. JAK2V617F = 1.61 
[range 0.19–8.32], p = 0.20) (Figure 7B) or CALR 
mutation status (CALRWT=1.48 [0.19–8.32] vs. 
CALRMUT = 1.08 [range 0.07–6.99], p = 0.45) 
(Figure 7C).
DISCUSSION
The relevance of Stathmin 1 in hematological 
malignancies has been well described in acute leukemia 
and lymphoma [7, 8, 9, 17, 21, 22]. However, studies 
addressing Stathmin 1 expression and function in 
MPN are still lacking. Using the JAK2V617F HEL cell 
Figure 4: Stathmin 1 silencing prevents microtubule instability induced by ruxolitinib treatment. Western blot analysis 
for p-Stathmin 1S16, Stathmin 1, alpha-tubulin acetylation (Ac-alpha-tubulinL40), p-STAT3Y705, p-JAK2Y221, caspase 3 (total and cleaved) and 
cleaved PARP1 levels in total cell extracts from shControl and shSTMN1 cells treated or not with ruxolitinib at 100 or 300 nM; membranes 
were reprobed with the antibody for detection of the respective total protein or actin, and developed with the ECL Western Blot Analysis 
System.
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model, we observed that Stathmin 1 silencing reduced 
cell proliferation and clonal growth. These findings 
are in agreement with our previous results in U937 
(myeloid leukemia cell line) and Namalwa (lymphoid 
leukemia cell line) cells [9], and in the BCR-ABL1 
K562 cells, as reported by two independent groups 
[10, 11]. Importantly, in HEL cells, Stathmin 1 silencing 
presented an additional effect, futher reducting of 
cell viability and increasing the apoptosis induced by 
ruxolitinib, a selective JAK1/2 inhibitor approved by 
the FDA for the treatment of intermediate and high-risk 
PMF. In PMF patients, results from a phase III clinical 
trial demonstrated that ruxolitinib is well-tolerated, 
reduces inflammatory cytokines and splenomegaly, 
and ameliorates constitutional symptoms, but does not 
reverse bone marrow fibrosis [23, 24, 25], suggesting a 
requirement of additional therapeutic strategies. Thus, 
preclinical studies using combined drugs are emerging 
in an attempt to improve the response to JAK inhibitors 
[26, 27, 28, 29, 30].
Ruxolitinib inhibits the constitutional activation 
of the JAK/STAT pathway, including STAT3 [15]. The 
cross-talk between STAT3 and Stathmin 1 signaling 
has been previously described in other cell lines from 
mice (NSC-34 mouse motor neuron-like hybrid cells), 
rats (PC12 pheochromocytoma cells) [31] and humans 
(Hut78 T-lymphoma cells [13], and SGC7901 and 
MGC803 gastric cancer cells [14]). STAT3 is a nuclear 
transcriptional activator that also induces microtubule 
stability by the inactivation of Stathmin 1 in the cytoplasm 
[13, 14]. We then identified the cross-talk between STAT3 
and Stathmin 1 signaling, also in HEL cells. Ruxolitinib 
downregulated STAT3 activity and STAT3/Stathmin 1 
association, releasing and activating Stathmin 1 and 
increasing microtubule instability. Corroborating 
this hypothesis, microtubule stability was rescued by 
Stathmin 1 silencing during ruxolitinib treatment.
In order to verify whether microtubule stability 
might be involved in the improved response of 
Stathmin 1 silenced cells to ruxolitinib, paclitaxel 
was used. Paclitaxel is a microtubule-targeted 
chemotherapeutic drug that induces microtubule 
polymerization, cell-cycle block at the metaphase-
anaphase transition and cell death, and is the first line 
Figure 5: Paclitaxel-induced microtubule stability improves ruxolitinib response. A. Apoptosis was detected by flow 
cytometry in HEL cells treated or not with paclitaxel (5 or 10 nM) and/or ruxolitinib (300 nM) using Annexin-V/PI staining method and 
a representative dot plot is illustrated. B. Bar graphs show the mean ± SD of six independent experiments; *p < 0.01 vs. untreated cells, 
#p ≤ 0.001 vs. ruxolitinib or paclitaxel monotherapy at the corresponding dose; Student’s t test. C. Cell viability was determined by MTT 
assay after 48 hours of incubation of HEL cells treated or not with paclitaxel (5 or 10 nM) and/or ruxolitinib (300 nM), and normalized 
by untreated HEL cells. Results are shown as mean ± SD of six independent experiments; *p ≤ 0.002 vs. untreated cells, #p ≤ 0.02 vs. 
ruxolitinib or paclitaxel monotherapy at the corresponding dose; Mann–Whitney test.
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treatment for specific solid tumors [32]. Interestingly, 
combined paclitaxel plus ruxolitinib treatment resulted 
in a significant reduction in cell viability and increased 
apoptosis, compared to monotherapy. In HEL cells, 
we then observed that paclitaxel treatment resulted 
in the same cell phenotype, as induced by Stathmin 1 
silencing. Our results are summarized and illustrated in 
Figure 7D.
Stathmin 1 expression was found to be upregulated 
in CD34+ cells from PMF patients. This finding can not 
yet be fully explained. In solid tumors, high Stathmin 1 
expression correlates with tumor growth and progression 
[3]. Of note, Stathmin 1 expression is associated with 
the proliferative potential of early hematopoietic 
progenitors [4]. Evidence from ex vivo studies indicate 
that PMF CD34+ cells have a proliferative advantage, 
when compared to normal CD34+ cells [33]. Thus, 
we speculate that the high expression of Stathmin 1 
in PB CD34+ PMF samples may contribute to the 
increased proliferative potential during early stages of 
cell differentiation. In contrast, in differentiated-MPN 
cells, Stathmin 1 inhibition and STAT3 activation 
Figure 6: Paclitaxel treatment leads to Stathmin 1S16 phosphorylation and potentiates ruxolitinib-induced caspase  
3/PARP1 cleavage. Western blot analysis for p-Stathmin 1S16, alpha-tubulin acetylation (Ac-alpha-acetylationL40), p-STAT3Y705, 
p-JAK2Y221, caspase 3 (total and cleaved) and cleaved PARP1 levels in total cell extracts from HEL cells treated, or not, with paclitaxel 
(5 or 10 nM) and/or ruxolitinib (300 nM); membranes were reprobed with the antibody for the detection of the respective total protein or 
actin, and developed with the ECL Western Blot analysis system.
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may predominate. An important study recently found 
that Stat3 deletion increased hematopoietic stem 
cell compartments in Jak2V617F knock-in mice [34], 
corroborating the relevance of STAT3 activation in 
differentiated cells. It should also be pointed out that 
gene expression analysis may not reflect the protein 
activity in primary MPN cells. Given the relevance of 
Stathmin 1 in HEL JAK2V617F cells, herein identified, 
further studies to better elucidate the participation of 
Stathmin 1/STAT3 axis in primary samples from PMF 
patients will be of importance.
We then proposed that an undesired effect 
of ruxolitinib treatment may constitute Stathmin 1 
activation and microtubule instability in JAK2V617F cells. 
Pharmacologic inhibition of Stathmin 1, in association 
with ruxolitinib treatment, may be an interesting strategy 
for inducing apoptosis in JAK2V617F cells. Our findings add 
new insights for Stathmin 1 involvement in the JAK2V617F 
signaling pathway in MPN.
MATERIALS AND METHODS
Primary samples
CD34+ cells were obtained from a total of 
22 peripheral blood (PB) samples collected from healthy 
donors (median age 44.5 years [range 37.3–51.1]) selected 
from the Blood Bank of the institution, and from 82 patients 
with MPN (median age 63.9 years [range 20.0–87.5]), 
including ET (n = 34), PV (n = 23) and PMF (n = 25) 
followed in the outpatient clinics of the University of 
Campinas. This study was approved by the Institutional 
and National Review Board in accordance to the Helsinki 
Declaration;. Patients were submitted to diagnosis evaluation 
according to the Word Health Organization 2008 criteria 
[35]. Seventy-six out of 82 patients were in regular use of 
hydroxyurea at the time of sampling, and none of the patients 
had received chemotherapy nor JAK1/2 inhibitor treatment 
before sampling. Among the patients, 52 were positive for 
Figure 7: Stathmin 1 mRNA levels in CD34+ cells from healthy donors and patients with myeloproliferative 
neoplasms. A. qPCR analysis of Stathmin 1 (STMN1) mRNA expression in peripheral blood (PB) CD34+ cells from healthy donors 
(HD), and from patients with a diagnosis of essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF), 
and from myeloproliferative neoplasms (MPN) patients stratified by B. JAK2V617F or C. CALR exon 9 mutational status. Horizontal lines 
indicate medians. The number of subjects and p values (Mann–Whitney test) are indicated in the graph. D. Potential model for Stathmin 1 
function in HEL cells; the constitutive activation of JAK2 by the V617F mutation leads to STAT3 phosphorylation, Stathmin 1 inhibition 
and microtubule stability. Ruxolitinib treatment inhibits JAK2 and STAT3 activity, decreasing the Stathmin 1 and STAT3 association, which 
consequently releases Stathmin 1 and leads to microtubule instability. Paclitaxel treatment overcomes the effect of ruxolitinib treatment, 
inhibiting Stathmin 1 and increasing microtubule stability. Abbreviations: Ac: acetylation.
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JAK2V617F mutation, 20 for CALR exon 9 indel mutation, 
9 were double negative for both mutations, and 1 patient was 
JAK2 wild-type but had not been tested for CALR mutation. 
JAK2 and CALR mutations were investigated as previously 
described [36, 37].
Cell culture and chemical reagents
The HEL cell line, which is known to harbor 
the JAK2V617F mutation, was obtained from ATCC, 
Philadelphia, PA, USA. Cells were cultured in RPMI 
containing 10% fetal bovine serum (FBS) and glutamine 
with penicillin/streptomycin and amphotericin B, 
and maintained at 37°C, 5% CO2. Ruxolitinib, a 
selective JAK1/2 inhibitor, was obtained from Novartis 
Pharmaceuticals (Basel, Switzerland). Paclitaxel, a 
microtubule-stabilizing drug, was obtained from INTAS 
Pharmaceuticals (Ahmedabd, India).
Quantitative PCR (qPCR) analysis
Quantitative PCR (qPCR) was performed with an 
ABI 7500 Sequence Detector System (Applied Biosystems, 
Foster City, CA, USA) with specific primers for 
Stathmin 1 (forward: AGCCCTCGGTCAAAAGAATC; 
reverse: TTCAAGACCTCAGCTTCATGGG) [38] 
and HPRT (hypoxanthine phosphoribosyltransferase 1; 
forward: GAACGTCTTGCTCGAGATGTGA; reverse: 
TCCAGCAGGTCAGCAAAGAAT). The relative 
quantification value was calculated using the equation 
2-ΔΔCT [39]. A negative ‘No Template Control’ was 
included for each primer pair. The dissociation protocol 
was performed at the end of each run to check for non-
specific amplification. Three replicas were run on the same 
plate for each sample.
Immunoprecipitation and Western blot
Equal amounts of protein were used for total extracts 
or for immunoprecipitation with specific antibodies, 
followed by SDS-PAGE and Western blot analysis with 
the indicated antibodies (carried out using the ECL™ 
Western Blotting Analysis System; Amersham Pharmacia 
Biotech Ltd., Buckinghamshire, UK), as previously 
described. Antibodies against p-Stathmin 1 (p-OP18 
S16, sc-12948-R), Stathmin 1 (OP18, sc-55531), alpha-
tubulin (sc-5286), JAK2 (sc-294), STAT3 (sc-7179), PARP1 
(sc-56197) and actin (sc-1616) were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Antibodies against 
p-JAK2 Y221 (#3774S), p-STAT3 Y705 (#9131S) and 
caspase 3 (#8G10) were from Cell Signaling Technology 
(Danvers, MA, USA). The antibody against acetyl-alpha-
tubulin L40 (ab24610) was from Abcam (Cambridge, 
MA, USA).
Confocal immunofluorescence microscopy
HEL cells treated or not with ruxolitinib (100 or 
300 nM) for 48 hours, were attached on cover slips 
coated with poly-L-lisine (1 mg/mL), fixed with 4% 
paraformaldehyde, permeabilized with 0.5% Triton 
X-PBS and blocked with 3% bovine serum albumin (BSA) 
PBS. Cells were then incubated with anti-alpha-tubulin 
Alexa Fluor® 488 conjugate (1:200 in 3% BSA PBS; 
eBioscience, San Diego, CA, USA) for 12 hours, and 
followed by three PBS washes. The slides were mounted 
in ProLong Gold Anti-Fade Mounting Medium with DAPI 
(Life Technologies, Carlsbad, CA, USA). Images were 
generated using a confocal laser-scanning microscope 
(LSM 510, Carl Zeiss, Welwyn Garden City, UK).
Lentivirus transduction
HEL cells were transduced with lentivirus-
mediated shRNA nonspecific control (sc-108080) or 
lentivirus-mediated shRNA targeting Stathmin 1 (containing 
three target-specific constructs; sc-36127-V) from Santa 
Cruz Biotechnology (Santa Cruz Biotechnology) and 
named shControl and shSTMN1 cells, respectively. 
Briefly, 2 ×105 cells were transduced with lentivirus by 
spinoculation at multiplicity of infection equal to 1 and 
selected by 0.75 μg/mL puromycin.
Methylthiazoletetrazolium (MTT) assay
Cell viability was measured by MTT assay. 
ShControl and shSTMN1 cells were serum-starved in 
0.5% FBS for 12 hours. A total of 2.5 × 104 cells per well 
were then cultured in a 96-well plate in RPMI 10% FBS in 
presence or not of ruxolitinib (100 and 300 nM). Paclitaxel 
(5 and 10 nM) was also used in the presence or not of 
ruxolitinib (300 nM). Next, 10 μL of a 5 mg/mL solution 
of MTT were added to the wells followed by incubation at 
37°C for 4 hours. The reaction was stopped using 100 μL 
of 0.1N HCl in anhydrous isopropanol. Cell viability was 
evaluated by measuring the absorbance at 570 nm, using 
an automated plate reader. All conditions were tested in 
six replicates.
Assessment of cell proliferation by Ki-67 staining
Cells were treated, or not, with different 
concentrations of ruxolitinib (100 or 300 nM) for 48 
hours, fixed with 70% ethanol and stored at −20°C. 
Ki-67 staining was performed following the manufacturer’s 
instructions (Ki-67 FITC clone B56; BD Bioscience, 
San Jose, CA, USA) and the mean of fluorescence 
intensity (M.F.I) was obtained by flow cytometry using a 
FACSCalibur (Becton Dickinson, San Jose, CA, USA). IgG 
isotype was used as negative control for each condition. 
Ten thousand events were acquired for each sample.
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Colony formation assay
Colony formation was carried out in semisolid 
methyl cellulose medium (1×103 cell/mL; MethoCult 
4230; StemCell Technologies Inc., Vancouver, BC, 
Canada). Colonies were detected after 10 days of culture 
by adding 1 mg/mL of MTT reagent and scored by Image 
J quantification software (U.S. National Institutes of 
Health, Bethesda, MD, USA).
Assessment of apoptosis by Annexin V and 
PI staining
Cells were seeded on 24-well plates and treated or 
not with different concentrations of ruxolitinib (100 or 
300 nM) and/or paclitaxel (5 or 10 nM) for 48 hours. 
Cells were then washed twice with ice cold PBS and 
resuspended in binding buffer containing 1 μg/mL PI 
and 1 μg/mL APC labeled Annexin-V. All specimens 
were analyzed by flow cytometry (FACSCalibur; Becton 
Dickinson) after incubation for 15 minutes at room 
temperature in a light-protected area. Ten thousand events 
were acquired for each sample.
Statistical analysis
Statistical analyses were performed using GraphPad 
Instat 5 (GraphPad Software, Inc., San. Diego, CA, USA). 
For comparisons, Student’s t-test or Mann–Whitney 
test were used for measured factors, as appropriate. 
A p value <0.05 was considered as statistically significant.
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